PDOX treatment also induced the highest level of circulating CD431B11+ CD4+ T cells on day 13 and day 18 post tumor challenge compared with other treatment groups (anti-OX40/CpG and anti-PD-L1) and untreated mice (Figure 3B). This evidence concerns the gene TNFRSF4 and neoplasm.